Scholarlink

Background <p>Between August and October 2021, before the Omicron wave and before COVID-19 vaccines became widely available in Tanzania, two studies estimated that half of the population in Zanzibar and Mwanza in Tanzania had SARS-CoV-2 antibodies. From May 2020 to Dec 2021, Tanzania adopted a very different COVID-19 mitigation strategy with no lockdowns or quarantines and limited community-level COVID-19 testing. We conducted population-based SARS-CoV-2 seroprevalence surveys in five regions of Tanzania between November 2021 and July 2022 to estimate community-level exposure to SARS-CoV-2and vaccine coverage.</p> Methods <p>Regionally representative cross-sectional serosurveys were progressively conducted via multistage cluster sampling in five regions in Tanzania. Twenty enumeration areas were randomly selected from each region. Seropositivity was determined using the WANTAI SARS-CoV-2 Ab ELISA kit.</p> Results <p>We found that nine out of every ten people living in five geographically dispersed regions in Tanzania had SARS-CoV-2 antibodies despite only 8% vaccination coverage in our sample.</p> Conclusion <p>Given the high seroprevalence of SARS-CoV-2 in these regions, targeting COVID-19 vaccination efforts to those at greater risk of severe disease may help maximize the public health impact.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Seroprevalence of SARS-CoV-2 in Tanzania: results from a cross-sectional study documenting the Omicron wave in five regions of Tanzania

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月3日

查看全文
  • Sayoki Godfrey Mfinanga,
  • Godfather Kimaro,
  • Aman Wilfred,
  • Nicholaus Mnyambwa,
  • Laura Steinhardt,
  • Stephen McCracken,
  • Lilian Joseph,
  • Medard Beyanga,
  • Jeanette Dawa,
  • Carolyne Nasimiyu,
  • Clara Lubinza,
  • Juma Kisuse,
  • George Judicate,
  • Senkoro Mbazi,
  • Esther Ngadaya,
  • Pawan Angra,
  • Mukurasi Kokuhabwa,
  • Mohamed F. Jalloh,
  • Grace Saguti,
  • Mahesh Swaminathan,
  • Aifello Sichalwe,
  • Njenga Kariuki,
  • Tumaini Nagu,
  • Wangeci Gatei

摘要

Background

Between August and October 2021, before the Omicron wave and before COVID-19 vaccines became widely available in Tanzania, two studies estimated that half of the population in Zanzibar and Mwanza in Tanzania had SARS-CoV-2 antibodies. From May 2020 to Dec 2021, Tanzania adopted a very different COVID-19 mitigation strategy with no lockdowns or quarantines and limited community-level COVID-19 testing. We conducted population-based SARS-CoV-2 seroprevalence surveys in five regions of Tanzania between November 2021 and July 2022 to estimate community-level exposure to SARS-CoV-2and vaccine coverage.

Methods

Regionally representative cross-sectional serosurveys were progressively conducted via multistage cluster sampling in five regions in Tanzania. Twenty enumeration areas were randomly selected from each region. Seropositivity was determined using the WANTAI SARS-CoV-2 Ab ELISA kit.

Results

We found that nine out of every ten people living in five geographically dispersed regions in Tanzania had SARS-CoV-2 antibodies despite only 8% vaccination coverage in our sample.

Conclusion

Given the high seroprevalence of SARS-CoV-2 in these regions, targeting COVID-19 vaccination efforts to those at greater risk of severe disease may help maximize the public health impact.